*  Bexarotene Amyloid Treatment for Alzheimer's Disease - Full Text View - ClinicalTrials.gov
Bexarotene Amyloid Treatment for Alzheimer's Disease (BEAT-AD). The safety and scientific validity of this study is the ... Intervention/treatment Active Comparator: Bexarotene treatment Arm 75 mg of Bexarotene BID for week 1, then increasing to 150 ... This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden ... This measures the change from baseline on treatment compared to placebo at week 4 on composite and regional beta amyloid burden ...
  https://clinicaltrials.gov/ct2/show/NCT01782742?cond=%22Alzheimer+disease+familial%22&rank=19
*  Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation - Drugs.com MedNews
Results from four studies of potential new treatments for Alzheimer s - even an unsuccessful late stage clinical trial - ... Home › News › Clinical Trials › Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse ... Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation. Print this page ... As an alternative to anti-amyloid therapies for Alzheimer's, researchers continue to examine a variety of treatments and ...
  https://www.drugs.com/clinical_trials/four-alzheimer-s-clinical-trials-address-variety-targets-amyloid-tau-synapse-formation-5192.html
*  Patients are needed to participate in a clinical research study for the treatment of Asymptomatic Amyloid-positive | Clinical...
Patients are needed to participate in a clinical research study for the treatment of Asymptomatic Amyloid-positive ... Patients are needed to participate in a clinical research study for the treatment of Asymptomatic Amyloid-positive ... The study will consist of a Screening Phase (approximately 90 days), treatment Phase (54 months) and follow-up Phase (7 to 28 ... The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo ...
  http://www.centerwatch.com/clinical-trials/listings/79059/asymptomatic-amyloid-positive-an-efficacy-safety-study/?&geo_lat=19.5345279&geo_lng=-99.1907364&radius=10
*  Anti-amyloid Oligomer Monoclonal Antibodies for Treatment of Parkinson's Disease | Parkinson's Disease
Anti-amyloid Oligomer Monoclonal Antibodies for Treatment of Parkinson's Disease. Alpha-Synuclein Therapeutics, 2010. ... that occur on amyloid aggregates from a number of different amyloids made from different protein sequences. For some of these ... Relevance to Diagnosis/Treatment of Parkinson s Disease: If we find antibodies that are specific for alpha-synuclein oligomers ... The goal of this project is to evaluate the interaction of a panel of conformation dependent, aggregation specific anti-amyloid ...
  https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=791
*  Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis | SpringerLink
Klein WL (2013) Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's ... Schnabel J (2011) Amyloid: little proteins, big clues. Nature 475(7355):S12-S14. doi:10.1038/475S12a PubMedGoogle Scholar ... Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280( ... Continuation of exercise is necessary to inhibit high fat diet-induced beta-amyloid deposition and memory deficit in amyloid ...
  https://link.springer.com/article/10.1007%2Fs00401-015-1386-3
*  A cetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with b-amyloid peptides - DRO
A cetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with b-amyloid peptides. Sáez- ... A cetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with b-amyloid peptides ... A cetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with b-amyloid peptides, Brain ... In this study we report that amyloid β-peptides (Aβ) increased AChE levels in both neuronal and astrocytic primary cultures, ...
  http://dro.deakin.edu.au/view/DU:30023810
*  Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the...
Chronic treatment with a functional γ-secretase inhibitor reduces β-amyloid burden and plaque pathology in PDAPP mice (Abstract ... Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease. ... Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease. ... Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease. ...
  http://jpet.aspetjournals.org/content/331/2/598
*  Lithium Treatment of APPSwDI/NOS2−/− Mice Leads to Reduced Hyperphosphorylated Tau, Increased Amyloid Deposition and Altered...
Our data suggest that lithium may be beneficial for the treatment of tauopathies but may not be beneficial for the treatment of ... amyloid pathology and neuronal loss we were interested in the effect anti-tau therapy would have on amyloid pathology, learning ... However, we found no apparent neuroprotection, no effect on spatial memory deficits and an increase in histological amyloid ... We recently developed a mouse model that progresses from amyloid pathology to tau pathology and neurodegeneration due to the ...
  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031993
*  Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ...
2004) Chronic treatment with the gamma secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters ... Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ- ... Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ- ... Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ- ...
  http://jpet.aspetjournals.org/content/313/2/902
*  New player in Alzheimer's disease pathogenesis identified
Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer's disease. July 27, 2017 For decades researches ... Aβ is created when gamma secretase cuts the amyloid precursor protein into smaller pieces. While Aβ is made in all human brains ... One step closer toward a treatment for Alzheimer's disease?. October 18, 2017 Scientists at the Massachusetts General Hospital ... "Our results suggest a new path toward future treatments for Alzheimer's disease," says Huaxi Xu, Ph.D., the Jeanne and Gary ...
  https://medicalxpress.com/news/2017-11-player-alzheimer-disease-pathogenesis.html
*  Search of: Alzheimer's disease - List Results - ClinicalTrials.gov
Primary Purpose: Treatment. *Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the ... Primary Purpose: Treatment. *Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) ... Bexarotene Amyloid Treatment for Alzheimer's Disease. *Alzheimer's Disease ... Primary Purpose: Treatment. *Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in cognitive ...
  https://clinicaltrials.gov/ct2/results?cond=Alzheimer
*  The treatment of peripartum cardiomyopathy | The British Journal of Cardiology
An update on treatments for amyloid heart disease BCS 2017 podcasts. Highlights from the meeting ... The treatment of peripartum cardiomyopathy. September 2004Br J Cardiol 2004;11:393-6 Leave a comment Click any image to enlarge ... Treatment options are similar to those for other forms of dilated cardiomyopathy. However, there are important considerations ... Close communication is required between cardiologists, obstetricians and neonatologists, not only for the treatment of the PPCM ...
  https://bjcardio.co.uk/2004/09/the-treatment-of-peripartum-cardiomyopathy/
*  Are New Cognitive Tests Ready For Preclinical Trials? | ALZFORUM
Anti-Amyloid Treatment in Asymptomatic AD (A4) Trial Further Reading. News. * As AD Trials Come of Age, Will Cognitive Tests ... Anti-Amyloid Treatment in Asymptomatic AD Trial 27 Dec 2011. * Detecting Familial AD Ever Earlier: Subtle Memory Signs 15 Years ... Cognitively normal people with brain amyloid perform worse on this task than do those without amyloid (see Rentz et al., 2011 ... will be the primary outcome measure in the upcoming Anti-Amyloid Treatment in Asymptomatic AD (A4) Trial. This study will ...
  https://www.alzforum.org/news/conference-coverage/are-new-cognitive-tests-ready-preclinical-trials
*  Clinical Trials on Alzheimer's Disease 2011 | ALZFORUM
Anti-Amyloid Treatment in Asymptomatic AD Trial 27 Dec 2011. Paper Citations. * Sperling RA, Bates JF, Cocchiarella AJ, ... so the hope was that it would provide a combined treatment effect across inflammatory and amyloid-related processes. In ... and proposed that amyloid-β oligomers cause synaptic dysfunction before the deposition of amyloid plaques in the brain (Selkoe ... RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003 Jul;9(7): ...
  https://www.alzforum.org/print-series/210586
*  Big Data Was the Big Theme at Shortened NIH Summit | ALZFORUM
Non-Amyloid Treatments: Inflammation, Epigenetics, Regeneration 11 May 2017. External Citations. * All of Us ... "Any notion that a quick path to prevention or treatment was going to emerge from 2012 … has turned out to be naïve," Collins ... It plans to gather data on 1 million Americans as a foundation to enable precision medicine, or medical treatment and care ...
  https://www.alzforum.org/news/conference-coverage/big-data-was-big-theme-shortened-nih-summit?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+alzforum%2FPpcR+%28Alzforum+News%29
*  Asymptomatic Alzheimer's Disease Anti-Amyloid Trial | Memory and Aging Center
Visits once every 4 weeks for 168 weeks ("treatment period"). *Potential open-label treatment options following the treatment ... Official Study Title: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study) ... Home > Research & Clinical Trials > Clinical Trials > Asymptomatic Alzheimer's Disease Anti-Amyloid Trial ... Duration of Participation: Up to 90 day screening period and 168 week treatment period ...
  https://memory.ucsf.edu/asymptomatic-alzheimer-disease-anti-amyloid-trial
*  Alzheimer's Research Disease unit at Yale School of Medicine Recruiting Subjects For Two Clinical Trials - Hartford Courant
That study is known as 'A4,' short for anti-amyloid treatment of asymptomatic Alzheimer's. The drug being investigated is ... Up to 1,000 people determined to be at risk because of elevated levels of the amyloid protein will be part of the study ... He said evidence suggests that an overabundance of peptides know as amyloid play a major role in development of Alzheimer's. ... Solanezumab may accelerate clearance of the soluble form of the amyloid protein, increasingly thought to be the most toxic form ...
  http://www.courant.com/health/hc-yale-alzheimers-clinical-trials-0926-20141001-story.html
*  Familial amyloid neuropathy - Wikipedia
"ATTR Famililial Amyloidosis". BU - Amyloid Treatment & Research Program. Archived from the original on 2008-07-06. Hammarström ... "Amyloid". "Amyloid". Akiya S, Nishio Y, Ibi K, et al. (July 1996). "Lattice corneal dystrophy type II associated with familial ... amyloid polyneuropathy World wide clinical trial for the evaluation of an investigational medicine for the possible treatment ... The familial amyloid neuropathies (or familial amyloidotic neuropathies, neuropathic heredofamilial amyloidosis, familial ...
  https://en.wikipedia.org/wiki/Familial_amyloid_neuropathy
*  Haemodialysis-associated amyloidosis - Wikipedia
ISBN 1-4160-2999-0. "BU Amyloid Treatment & Research Program". Archived from the original on 2008-07-20. ...
  https://en.wikipedia.org/wiki/Haemodialysis-associated_amyloidosis
*  AA amyloidosis - Wikipedia
"AA Amyloidosis". BU Amyloid Treatment & Research Program. Daisuke Katagiri; Eisei Noiri; Fumihiko Hinoshita (2013). "Multiple ... Kiacta, inhibits the formation and deposition of the amyloid A fibrils into the tissues. There is evidence that eating amyloid ... There are currently no approved treatments for systemic AA amyloidosis. The current standard of care includes treatments for ... Nevertheless, because amyloid fibers can be detected in muscle in low amounts, it raises some concern about whether people ...
  https://en.wikipedia.org/wiki/AA_amyloidosis
*  AL amyloidosis - Wikipedia
... information on AL amyloidosis Stanford University Amyloid Center Boston University Amyloid Treatment and Research Program ... "BU: Amyloid Treatment & Research Program". Archived from the original on 2008-07-20. Chakra P. Chaulagain, MD; Raymond L. ... The most effective treatment is autologous bone marrow transplants with stem cell rescues. However many patients are too weak ... Amyloid light-chain (AL) amyloidosis, primary systemic amyloidosis (PSA) or just primary amyloidosis is the most common form of ...
  https://en.wikipedia.org/wiki/AL_amyloidosis
*  Hemichannels Are Required for Amyloid β-Peptide-Induced Degranulation and Are Activated in Brain Mast Cells of APPswe/PS1dE9...
With respect to amyloid treatment, we found that both Cx43 [La3+ (147.6 ± 19.7%, *p , 0.05, n = 3) and Gap26 (138.7 ± 16.9%, *p ... Such an increase was already detectable in young mice before the appearance of amyloid plaques. In this model, when the amyloid ... 2010) Astroglial connexin immunoreactivity is specifically altered at beta-amyloid plaques in beta-amyloid precursor protein/ ... MCs under control conditions and after amyloid treatment, the slopes were 1.5 ± 0.1 pA/s and 2.2 ± 0.1 pA/ms, respectively (n ...
  http://www.jneurosci.org/content/35/25/9526
*  Collecting Samples From Patients With Primary Systemic Amyloidosis
Referred to the Amyloid Treatment and Research Center at Boston University Medical. Center. PRIOR CONCURRENT THERAPY:. - Not ... Data, Tissue, Blood, and Urine Repository for Amyloid Diseases. Trial Phase:. N/A. Minimum Age:. 18 Years. Maximum Age:. N/A ... features unique to amyloid proteins. Tissue samples are analyzed for biochemical and. biophysical properties and for post- ... Data, Tissue, Blood, and Urine Repository for Amyloid Diseases. OBJECTIVES:. - To establish and maintain a database of clinical ...
  http://www.knowcancer.com/cancer-trials/NCT00898235/
*  Alzheimer's Drug Treatment Horizon | Research Center | Alzheimer's Association
... learn about beta-amyloid and tau protein targets and find latest clinical trials and studies. ... dementia and memory loss drug treatment research updates - ... The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease ... and even using antibodies against beta-amyloid to clear it from the brain. Current drug in research that targets beta-amyloid: ... Treatment Horizon. "The science of Alzheimer's has advanced to show potential underlying drivers of the disease. And we have ...
  https://alz.org/research/science/alzheimers_treatment_horizon.asp
*  Frontiers | Possible role of hemichannels in cancer | Physiology
... treatment with amyloid beta peptide (Orellana et al., 2011), exposure to hypotonic stress (Lu et al., 2012), after spinal cord ... 2011). Amyloid β-induced death in neurons involves glial and neuronal hemichannels. J. Neurosci. 31, 4962-4977. doi: 10.1523/ ... Roger, S., and Pelegrin, P. (2011). P2X7 receptor antagonism in the treatment of cancers. Expert Opin. Invest. Drugs 20, 875- ... In androgen dependent (LNCaP) and androgen-independent human prostate cancer cell lines (DU145 and PC3), treatment with the ...
  https://www.frontiersin.org/articles/10.3389/fphys.2014.00237/full